// App-Quantinova.ai

2266 : Metabolism and Disposition of Betrixaban and Its Lack of Interaction with Major CYP Enzymes.

Researchers

Presenter

  • Christine Ye

Principal Investigators

  • Yonghong Song

  • Todd Lorenz

  • Daniel Gretler

  • Joseph L Lambing

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Portola Pharmaceutic

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • Apurinic/Apyrimidinic Endodeoxyribonuclease 1

  • Cytochrome P450 Family 3 Subfamily A Member 4

  • Cytochrome P450 2C19

Drug/Treatment

  • Dextromethorphan

  • Oralin

  • betrixaban

  • Midazolam

Outcome

  • N/A

Study Design

  • open label

  • drug-drug interaction

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved